{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:23:42Z","timestamp":1793701422397,"version":"4.5.1"},"reference-count":244,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["0095\/2024\/RIB2"],"award-info":[{"award-number":["0095\/2024\/RIB2"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.pharmr.2026.100125","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:18:33Z","timestamp":1771373913000},"page":"100125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Emerging natural products against obesity and metabolic dysfunction-associated steatotic liver disease\/metabolic dysfunction-associated steatohepatitis: Direct target discovery and mechanistic insights"],"prefix":"10.1016","volume":"78","author":[{"given":"Wei","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0607-9625","authenticated-orcid":false,"given":"He","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juntao","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7700-8041","authenticated-orcid":false,"given":"Yi Zhun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10481","key":"10.1016\/j.pharmr.2026.100125_bib1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2026.100125_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.metabol.2018.09.005","article-title":"The epidemiology of obesity","volume":"92","author":"Chooi","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmr.2026.100125_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113936","article-title":"Inhibition of ZFP281\/ZNF281-RIPK1\/RIPK3\/MLKL signaling in hepatocytes by pterostilbene relieves hepatic lipometabolic disorder and inflammation in non-alcoholic steatohepatitis","volume":"146","author":"Lu","year":"2025","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib4","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","article-title":"New and emerging treatments for metabolic dysfunction-associated steatohepatitis","volume":"36","author":"Tincopa","year":"2024","journal-title":"Cell Metab"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100125_bib5","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1016\/j.apsb.2021.07.006","article-title":"Ablation of Akt2 and AMPK\u03b12 rescues high fat diet-induced obesity and hepatic steatosis through Parkin-mediated mitophagy","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"10504","key":"10.1016\/j.pharmr.2026.100125_bib6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100125_bib7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100125_bib8","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100125_bib9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100125_bib10","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100125_bib11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100125_bib12","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J Nat Prod"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.apsb.2019.11.017","article-title":"Herbal drug discovery for the treatment of nonalcoholic fatty liver disease","volume":"10","author":"Yan","year":"2020","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100125_bib14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100125_bib15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages","volume":"73","author":"Lefere","year":"2020","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100125_bib16","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41574-021-00529-7","article-title":"GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease","volume":"17","author":"Wang","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib17","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jhep.2013.12.012","article-title":"Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation","volume":"60","author":"Casta\u00f1o","year":"2014","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","article-title":"Integrative metabolism in MASLD and MASH: pathophysiology and emerging mechanisms","volume":"83","author":"Steinberg","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s13668-025-00611-w","article-title":"Phytochemicals in obesity management: mechanisms and clinical perspectives","volume":"14","author":"Rao","year":"2025","journal-title":"Curr Nutr Rep"},{"key":"10.1016\/j.pharmr.2026.100125_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106925","article-title":"Natural products in non-alcoholic fatty liver disease (NAFLD): novel lead discovery for drug development","volume":"196","author":"Wang","year":"2023","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100125_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.iliver.2024.100131","article-title":"New approaches to the treatment of metabolic dysfunction-associated steatotic liver with natural products","volume":"3","author":"Yadav","year":"2024","journal-title":"ILIVER"},{"issue":"6953","key":"10.1016\/j.pharmr.2026.100125_bib22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature01921","article-title":"Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha","volume":"425","author":"Fu","year":"2003","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100125_bib23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cmet.2008.08.005","article-title":"The lipid messenger OEA links dietary fat intake to satiety","volume":"8","author":"Schwartz","year":"2008","journal-title":"Cell Metab"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100125_bib24","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.tem.2013.03.001","article-title":"A fatty gut feeling","volume":"24","author":"Piomelli","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2026.100125_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104770","article-title":"Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: effects on metabolic parameters, anthropometric indices, and expression of PPAR-\u03b1, UCP1, and UCP2 genes","volume":"156","author":"Tutunchi","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmr.2026.100125_bib26","article-title":"Dietary Supplementation of RiduZone (Oleoylethanolamide\/OEA Capsule) Results in Weight Loss in Humans: The First-in-Human Case Studies (Poster #CHI19)","author":"Hallmark","year":"2016","journal-title":"Overcoming Obes 2016 Conf"},{"key":"10.1016\/j.pharmr.2026.100125_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.physbeh.2017.02.034","article-title":"Oleoylethanolamide: a fat ally in the fight against obesity","volume":"176","author":"Brown","year":"2017","journal-title":"Physiol Behav"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cell.2008.10.043","article-title":"N-acylphosphatidylethanolamine, a gut- Derived circulating factor induced by fat ingestion, inhibits food intake","volume":"135","author":"Gillum","year":"2008","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3920\/BM2020.0057","article-title":"Short chain fatty acids in human gut and metabolic health","volume":"11","author":"Blaak","year":"2020","journal-title":"Benef Microbes"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100125_bib30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-019-0157-3","article-title":"The role of short-chain fatty acids in microbiota\u2013gut\u2013brain communication","volume":"16","author":"Dalile","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2026.100125_bib31","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1038\/ncomms2852","article-title":"The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43","volume":"4","author":"Kimura","year":"2013","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100125_bib32","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2337\/db08-1637","article-title":"Butyrate improves insulin sensitivity and increases energy expenditure in mice","volume":"58","author":"Gao","year":"2009","journal-title":"Diabetes"},{"issue":"43","key":"10.1016\/j.pharmr.2026.100125_bib33","doi-asserted-by":"crossref","first-page":"16767","DOI":"10.1073\/pnas.0808567105","article-title":"Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41","volume":"105","author":"Samuel","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib34","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2337\/db11-1019","article-title":"Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein\u2013coupled receptor FFAR2","volume":"61","author":"Tolhurst","year":"2012","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100125_bib35","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1136\/gutjnl-2014-307913","article-title":"Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults","volume":"64","author":"Chambers","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.pharmr.2026.100125_bib36","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jare.2024.12.002","article-title":"Dissecting the anti-obesity components of ginseng: how ginseng polysaccharides and ginsenosides target gut microbiota to suppress high-fat diet-induced obesity","volume":"75","author":"Luo","year":"2025","journal-title":"J Adv Res"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100125_bib37","article-title":"Gut microbiota-butyrate-PPAR\u03b3 axis modulates adipose regulatory T cell population","volume":"12","author":"Chen","year":"2025","journal-title":"Adv Sci"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100125_bib38","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.cmet.2025.04.013","article-title":"Acetylated cellulose suppresses body mass gain through gut commensals consuming host-accessible carbohydrates","volume":"37","author":"Takeuchi","year":"2025","journal-title":"Cell Metab"},{"issue":"6704","key":"10.1016\/j.pharmr.2026.100125_bib39","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/27376","article-title":"Leptin and the regulation of body weight in mammals","volume":"395","author":"Friedman","year":"1998","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-physiol-042324-100259","article-title":"Leptin: 30 years later","volume":"88","author":"Ahima","year":"2026","journal-title":"Annu Rev Physiol"},{"issue":"7818","key":"10.1016\/j.pharmr.2026.100125_bib41","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41586-020-2527-y","article-title":"A leptin\u2013BDNF pathway regulating sympathetic innervation of adipose tissue","volume":"583","author":"Wang","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib42","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41467-024-46783-x","article-title":"A negative feedback loop between TET2 and leptin in adipocyte regulates body weight","volume":"15","author":"Zeng","year":"2024","journal-title":"Nat Commun"},{"issue":"8041","key":"10.1016\/j.pharmr.2026.100125_bib43","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41586-024-08108-2","article-title":"Leptin-activated hypothalamic BNC2 neurons acutely suppress food intake","volume":"636","author":"Tan","year":"2024","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100125_bib44","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/90984","article-title":"The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100125_bib45","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nm1557","article-title":"Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions","volume":"13","author":"Yamauchi","year":"2007","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2023.12.003","article-title":"New advances of adiponectin in regulating obesity and related metabolic syndromes","volume":"14","author":"Han","year":"2024","journal-title":"J Pharm Anal"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100125_bib47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41422-025-01078-8","article-title":"Raptin, a sleep-induced hypothalamic hormone, suppresses appetite and obesity","volume":"35","author":"Xie","year":"2025","journal-title":"Cell Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100125_bib48","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","article-title":"Hepatic fibroblast growth factor 21 is regulated by PPAR a and is a key mediator of hepatic lipid metabolism in ketotic states","volume":"5","author":"Badman","year":"2007","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nm.3014","article-title":"Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine","volume":"19","author":"Kim","year":"2013","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100125_bib50","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s42255-025-01236-7","article-title":"Dietary protein restriction elevates FGF21 levels and energy requirements to maintain body weight in lean men","volume":"7","author":"Nicolaisen","year":"2025","journal-title":"Nat Metab"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100125_bib51","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.cmet.2025.05.011","article-title":"FGF21 promotes longevity in diet-induced obesity through metabolic benefits independent of growth suppression","volume":"37","author":"Gliniak","year":"2025","journal-title":"Cell Metab"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100125_bib52","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1530\/EC-20-0152","article-title":"FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation","volume":"9","author":"Keinicke","year":"2020","journal-title":"Endocr Connect"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100125_bib53","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cmet.2025.04.014","article-title":"FGF21 reverses MASH through coordinated actions on the CNS and liver","volume":"37","author":"Rose","year":"2025","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7150\/ijbs.73936","article-title":"Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine","volume":"19","author":"Tan","year":"2023","journal-title":"Int J Biol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), pegylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized Phase 2 study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity"},{"issue":"10165","key":"10.1016\/j.pharmr.2026.100125_bib56","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100125_bib57","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100125_bib58","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10504","key":"10.1016\/j.pharmr.2026.100125_bib59","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100125_bib60","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(25)00067-6","article-title":"Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial","volume":"10","author":"Loomba","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7926","key":"10.1016\/j.pharmr.2026.100125_bib61","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41586-022-05041-0","article-title":"Apoptotic brown adipocytes enhance energy expenditure via extracellular inosine","volume":"609","author":"Niemann","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib62","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.tcb.2023.04.007","article-title":"Inosine: novel activator of brown adipose tissue and energy homeostasis","volume":"34","author":"Pfeifer","year":"2024","journal-title":"Trends Cell Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib63","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41392-022-01218-1","article-title":"Fire up the pyre: inosine thermogenic signaling for obesity therapy","volume":"7","author":"Willemsen","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"7915","key":"10.1016\/j.pharmr.2026.100125_bib64","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41586-022-04828-5","article-title":"An exercise-inducible metabolite that suppresses feeding and obesity","volume":"606","author":"Li","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib65","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cell.2024.10.032","article-title":"A \u03b2-hydroxybutyrate shunt pathway generates anti-obesity ketone metabolites","volume":"188","author":"Moya-Garzon","year":"2024","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100125_bib66","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s42255-025-01246-5","article-title":"Human gut microbial aromatic amino acid and related metabolites prevent obesity through intestinal immune control","volume":"7","author":"Jiang","year":"2025","journal-title":"Nat Metab"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100125_bib67","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/procel\/pwae014","article-title":"Dietary pyruvate targets cytosolic phospholipase A2 to mitigate inflammation and obesity in mice","volume":"15","author":"Hasan","year":"2024","journal-title":"Protein Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib68","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-025-56105-4","article-title":"Lactobacillus reuteri ZJ617 attenuates metabolic syndrome via microbiota-derived spermidine","volume":"16","author":"Ma","year":"2025","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100125_bib69","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/gutjnl-2020-323715","article-title":"Dietary macronutrients and the gut microbiome: a precision nutrition approach to improve cardiometabolic health","volume":"71","author":"Jardon","year":"2022","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib70","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/mnfr.201300333","article-title":"Human pharmacokinetics of xanthohumol, an antihyperglycemic flavonoid from hops","volume":"58","author":"Legette","year":"2014","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.pharmr.2026.100125_bib71","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.abb.2016.03.008","article-title":"Xanthohumol improves dysfunctional glucose and lipid metabolism in diet-induced obese C57BL\/6J mice","volume":"599","author":"Miranda","year":"2016","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib72","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41598-017-18992-6","article-title":"Non-estrogenic xanthohumol derivatives mitigate insulin resistance and cognitive impairment in high-fat diet-induced obese mice","volume":"8","author":"Miranda","year":"2018","journal-title":"Sci Rep"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100125_bib73","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.3390\/foods12234214","article-title":"The hepatic Antisteatosis effect of xanthohumol in high-fat diet-fed rats entails activation of AMPK as a possible protective mechanism","volume":"12","author":"Atteia","year":"2023","journal-title":"Foods"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib74","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12986-018-0277-8","article-title":"Novel anti-obesity effects of beer hops compound xanthohumol: role of AMPK signaling pathway","volume":"15","author":"Samuels","year":"2018","journal-title":"Nutr Metab"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100125_bib75","doi-asserted-by":"crossref","first-page":"19000","DOI":"10.1074\/jbc.M112.445452","article-title":"A metabolomics-driven elucidation of the anti-obesity mechanisms of xanthohumol","volume":"288","author":"Kirkwood","year":"2013","journal-title":"J Biol Chem"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100125_bib76","article-title":"Targeting the liver-brain axis with hop-derived flavonoids improves lipid metabolism and cognitive performance in mice","volume":"64","author":"Paraiso","year":"2020","journal-title":"Mol Nutr Food Res"},{"issue":"33","key":"10.1016\/j.pharmr.2026.100125_bib77","doi-asserted-by":"crossref","first-page":"20565","DOI":"10.1074\/jbc.M115.656975","article-title":"Xanthohumol improves diet-induced obesity and fatty liver by suppressing Sterol Regulatory Element-binding Protein (SREBP) activation","volume":"290","author":"Miyata","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100125_bib78","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.66398","article-title":"Tetrahydroxanthohumol, a xanthohumol derivative, attenuates high-fat diet-induced hepatic steatosis by antagonizing PPAR\u03b3","volume":"10","author":"Zhang","year":"2021","journal-title":"eLife"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib79","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s40168-023-01637-4","article-title":"Reducing gut microbiome-driven adipose tissue inflammation alleviates metabolic syndrome","volume":"11","author":"Newman","year":"2023","journal-title":"Microbiome"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100125_bib80","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jtcme.2017.08.012","article-title":"An update on natural compounds in the remedy of diabetes mellitus: a systematic review","volume":"8","author":"Choudhury","year":"2018","journal-title":"J Tradit Complement Med"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100125_bib81","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1002\/ptr.7144","article-title":"Quercetin and metabolic syndrome: a review","volume":"35","author":"Hosseini","year":"2021","journal-title":"Phytother Res"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100125_bib82","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1002\/ptr.7575","article-title":"Quercetin improves high-fat diet-induced obesity by modulating gut microbiota and metabolites in C57BL\/6J mice","volume":"36","author":"Su","year":"2022","journal-title":"Phytother Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib83","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2390136","article-title":"Quercetin activates energy expenditure to combat metabolic syndrome through modulating gut microbiota-bile acids crosstalk in mice","volume":"16","author":"Zhu","year":"2024","journal-title":"Gut Microbes"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100125_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202412865","article-title":"Quercetin-driven Akkermansia muciniphila alleviates obesity by modulating bile acid metabolism via an ILA\/m6A\/CYP8B1 signaling","volume":"12","author":"Liu","year":"2025","journal-title":"Adv Sci"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100125_bib85","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1002\/ptr.7499","article-title":"Resveratrol ameliorates muscle atrophy in chronic kidney disease via the axis of SIRT1\/FoxO1","volume":"36","author":"Wang","year":"2022","journal-title":"Phytother Res"},{"key":"10.1016\/j.pharmr.2026.100125_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.116882","article-title":"Resveratrol alleviates inflammatory bowel disease by inhibiting JAK2\/STAT3 pathway activity via the reduction of O-GlcNAcylation of STAT3 in intestinal epithelial cells","volume":"484","author":"Yaqin","year":"2024","journal-title":"Toxicol Appl Pharmacol"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100125_bib87","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.3390\/nu14142870","article-title":"Implications of resveratrol in obesity and insulin resistance: a state-of-the-art review","volume":"14","author":"Barber","year":"2022","journal-title":"Nutrients"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100125_bib88","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.3390\/molecules26092495","article-title":"The role of resveratrol in human male fertility","volume":"26","author":"Mongio\u00ec","year":"2021","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100125_bib89","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3390\/nu14071424","article-title":"Resveratrol for weight loss in obesity: an assessment of randomized control trial designs in ClinicalTrials.gov","volume":"14","author":"Hillsley","year":"2022","journal-title":"Nutrients"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100125_bib90","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.freeradbiomed.2020.04.013","article-title":"Resveratrol reduces obesity in high-fat diet-fed mice via modulating the composition and metabolic function of the gut microbiota","volume":"156","author":"Wang","year":"2020","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib91","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2446391","article-title":"Gut microbiota-derived 4-hydroxyphenylacetic acid from resveratrol supplementation prevents obesity through SIRT1 signaling activation","volume":"17","author":"Wang","year":"2025","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib92","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.163","article-title":"Glucomannan promotes Bacteroides ovatus to improve intestinal barrier function and ameliorate insulin resistance","volume":"3","author":"Nie","year":"2024","journal-title":"Imeta"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100125_bib93","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 receptor agonists and cancer risk in adults with obesity","volume":"11","author":"Dai","year":"2025","journal-title":"JAMA Oncol"},{"issue":"8061","key":"10.1016\/j.pharmr.2026.100125_bib94","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-025-08683-y","article-title":"Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide","volume":"641","author":"Coassolo","year":"2025","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100125_bib95","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity?","volume":"49","author":"Melson","year":"2024","journal-title":"Int J Obes"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib96","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pharmthera.2009.06.005","article-title":"Gut hormones: implications for the treatment of obesity","volume":"124","author":"Neary","year":"2009","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib97","doi-asserted-by":"crossref","first-page":"9100","DOI":"10.1038\/s41467-024-53118-3","article-title":"Annonaceous acetogenins mimic AA005 targets mitochondrial trifunctional enzyme alpha subunit to treat obesity in male mice","volume":"15","author":"Han","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib98","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lfs.2005.12.027","article-title":"Hyperforin: more than an antidepressant bioactive compound?","volume":"79","author":"Medina","year":"2006","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib99","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ptr.8063","article-title":"Cellular neurobiology of hyperforin","volume":"38","author":"Bouron","year":"2024","journal-title":"Phytother Res"},{"key":"10.1016\/j.pharmr.2026.100125_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.phytochem.2022.113526","article-title":"Hyperforin: a natural lead compound with multiple pharmacological activities","volume":"206","author":"Li","year":"2023","journal-title":"Phytochemistry"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100125_bib101","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.cmet.2021.02.007","article-title":"The phytochemical hyperforin triggers thermogenesis in adipose tissue via a Dlat-AMPK signaling axis to curb obesity","volume":"33","author":"Chen","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2026.100125_bib102","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jare.2024.11.035","article-title":"Targeting Dlat-Trpv3 pathway by hyperforin elicits non-canonical promotion of adipose thermogenesis as an effective anti-obesity strategy","volume":"75","author":"Lu","year":"2025","journal-title":"J Adv Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib103","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1016\/j.apsb.2022.01.006","article-title":"Equisetin is an anti-obesity candidate through targeting 11\u03b2-HSD1","volume":"12","author":"Xu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.pharmr.2026.100125_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153507","article-title":"Matrine, as a CaSR agonist promotes intestinal GLP-1 secretion and improves insulin resistance in diabetes mellitus","volume":"84","author":"Guo","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmr.2026.100125_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106136","article-title":"Matrine counteracts obesity in mice via inducing adipose thermogenesis by activating HSF1\/PGC-1\u03b1 axis","volume":"177","author":"Li","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmr.2026.100125_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.628988","article-title":"Baicalin prevents myocardial ischemia\/reperfusion injury through inhibiting ACSL4 mediated ferroptosis","volume":"12","author":"Fan","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib107","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/pharmaceutics15010257","article-title":"pH-responsive hydrogel as a potential oral delivery system of baicalin for prolonging gastroprotective activity","volume":"15","author":"Xu","year":"2023","journal-title":"Pharmaceutics"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100125_bib108","doi-asserted-by":"crossref","first-page":"E5896","DOI":"10.1073\/pnas.1801745115","article-title":"Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis","volume":"115","author":"Dai","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2026.100125_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.174913","article-title":"Baicalin promotes the activation of brown and white adipose tissue through AMPK\/PGC1\u03b1 pathway","volume":"922","author":"Zhang","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100125_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.118355","article-title":"Baicalin suppresses macrophage JNK-mediated adipose tissue inflammation to mitigate insulin resistance in obesity","volume":"332","author":"Zhu","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.pharmr.2026.100125_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155296","article-title":"Baicalin ameliorates insulin resistance and regulates hepatic glucose metabolism via activating insulin signaling pathway in obese pre-diabetic mice","volume":"124","author":"Miao","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmr.2026.100125_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153869","article-title":"Baicalin protects against insulin resistance and metabolic dysfunction through activation of GALR2\/GLUT4 signaling","volume":"95","author":"Yu","year":"2022","journal-title":"Phytomedicine"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100125_bib113","article-title":"One-pot controllable assembly of a baicalin-condensed aptamer nanodrug for synergistic anti-obesity","volume":"19","author":"Tian","year":"2023","journal-title":"Small"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100125_bib114","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1021\/acs.jafc.5b05841","article-title":"Anti-inflammatory and antinociceptive constituents of Atractylodes japonica Koidzumi","volume":"64","author":"Chen","year":"2016","journal-title":"J Agric Food Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib115","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1111\/jcmm.14148","article-title":"Atractylenolide II reverses the influence of lncRNA XIST\/miR-30a-5p\/ROR1 axis on chemo-resistance of colorectal cancer cells","volume":"23","author":"Zhang","year":"2019","journal-title":"J Cell Mol Med"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100125_bib116","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s12272-021-01342-6","article-title":"Atractylenolides (I, II, and III): a review of their pharmacology and pharmacokinetics","volume":"44","author":"Deng","year":"2021","journal-title":"Arch Pharm Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib117","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cmet.2022.11.012","article-title":"Discovery of a potent allosteric activator of DGKQ that ameliorates obesity-induced insulin resistance via the sn-1,2-DAG-PKC\u03b5 signaling axis","volume":"35","author":"Zheng","year":"2023","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001517","article-title":"Camptothecin effectively treats obesity in mice through GDF15 induction","volume":"20","author":"Lu","year":"2022","journal-title":"PLoS Biol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100125_bib119","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202405175","article-title":"Integrated stress response activator halofuginone protects mice from diabetes-like phenotypes","volume":"223","author":"Rai","year":"2024","journal-title":"J Cell Biol"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100125_bib120","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adt3142","article-title":"The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21","volume":"11","author":"Xu","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.pharmr.2026.100125_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107696","article-title":"The potential of artemisinins as anti-obesity agents via modulating the immune system","volume":"216","author":"Shen","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100125_bib122","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/cr.2016.108","article-title":"Artemisinin derivatives prevent obesity by inducing browning of WAT and enhancing BAT function","volume":"26","author":"Lu","year":"2016","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib123","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbrc.2016.04.109","article-title":"Artesunate inhibits adipogeneis in 3T3-L1 preadipocytes by reducing the expression and\/or phosphorylation levels of C\/EBP-\u03b1, PPAR-\u03b3, FAS, perilipin A, and STAT-3","volume":"474","author":"Jang","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib124","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41467-024-45452-3","article-title":"Artesunate treats obesity in male mice and non-human primates through GDF15\/GFRAL signalling axis","volume":"15","author":"Guo","year":"2024","journal-title":"Nat Commun"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100125_bib125","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.7150\/thno.36505","article-title":"Inhibition of HSP90\u03b2 improves lipid disorders by promoting mature SREBPs degradation via the ubiquitin-proteasome system","volume":"9","author":"Zheng","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.pharmr.2026.100125_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105291","article-title":"Corylin reduces obesity and insulin resistance and promotes adipose tissue browning through SIRT-1 and \u03b23-AR activation","volume":"164","author":"Chen","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmr.2026.100125_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105572","article-title":"Celastrol in metabolic diseases: progress and application prospects","volume":"167","author":"Xu","year":"2021","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib128","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.cell.2015.05.011","article-title":"Treatment of obesity with celastrol","volume":"161","author":"Liu","year":"2015","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100125_bib129","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.cmet.2015.08.005","article-title":"Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1\u03b1 transcriptional axis","volume":"22","author":"Ma","year":"2015","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100125_bib130","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41591-019-0358-x","article-title":"IL1R1 is required for celastrol\u2019s leptin-sensitization and antiobesity effects","volume":"25","author":"Feng","year":"2019","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib131","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4093\/dmj.2019.0124","article-title":"Effects of microbiota on the treatment of obesity with the natural product celastrol in rats","volume":"44","author":"Hu","year":"2020","journal-title":"Diabetes Metab J"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100125_bib132","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.641","article-title":"Celastrol prevents high-fat diet-induced obesity by promoting white adipose tissue browning","volume":"11","author":"Wang","year":"2021","journal-title":"Clin Transl Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100125_bib133","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.bbadis.2019.02.002","article-title":"Treatment with celastrol protects against obesity through suppression of galanin-induced fat intake and activation of PGC-1\u03b1\/GLUT4 axis-mediated glucose consumption","volume":"1865","author":"Fang","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.pharmr.2026.100125_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115231","article-title":"Puerarin improves busulfan-induced disruption of spermatogenesis by inhibiting MAPK pathways","volume":"165","author":"Li","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100125_bib135","doi-asserted-by":"crossref","first-page":"7187","DOI":"10.1021\/acs.jafc.3c09601","article-title":"Puerarin induces macrophage M2 polarization to exert antinonalcoholic steatohepatitis pharmacological activity via the activation of autophagy","volume":"72","author":"Fang","year":"2024","journal-title":"J Agric Food Chem"},{"issue":"8035","key":"10.1016\/j.pharmr.2026.100125_bib136","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41586-024-07929-5","article-title":"A brain-to-gut signal controls intestinal fat absorption","volume":"634","author":"Lyu","year":"2024","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100125_bib137","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/gutjnl-2020-323188","article-title":"NAFLD-related mortality: simple hepatic steatosis is not as \u201cbenign\u201d as thought","volume":"70","author":"Tilg","year":"2021","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100125_bib138","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41575-024-00938-9","article-title":"Envisioning how to advance the MASH field","volume":"21","author":"Allen","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib139","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41591-024-03301-2","article-title":"Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Pulaski","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2026.100125_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113927","article-title":"Modulation of SIRT1-mediated signaling cascades in the liver contributes to the amelioration of nonalcoholic steatohepatitis in high fat fed middle-aged LDL receptor knockout mice by dihydromyricetin","volume":"175","author":"Zeng","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmr.2026.100125_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112957","article-title":"Update of Indoles: promising molecules for ameliorating metabolic diseases","volume":"150","author":"Hu","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharmr.2026.100125_bib142","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pharmthera.2018.01.006","article-title":"Discovery of Leonuri and therapeutical applications: from bench to bedside","volume":"188","author":"Zhu","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100125_bib143","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1161\/STROKEAHA.110.589895","article-title":"Leonurine protects middle cerebral artery occluded rats through antioxidant effect and regulation of mitochondrial function","volume":"41","author":"Loh","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.pharmr.2026.100125_bib144","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3389\/fphar.2018.01468","article-title":"Anti-hypercholesterolemic effects and a good safety profile of SCM-198 in animals: from ApoE knockout mice to rhesus monkeys","volume":"9","author":"Suguro","year":"2018","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100125_bib145","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3390\/antiox11071338","article-title":"Leonurine attenuates obesity-related vascular dysfunction and inflammation","volume":"11","author":"Shi","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.pharmr.2026.100125_bib146","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.biopha.2018.12.003","article-title":"Novel hepatoprotective role of leonurine hydrochloride against experimental non-alcoholic steatohepatitis mediated via AMPK\/SREBP1 signaling pathway","volume":"110","author":"Zhang","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100125_bib147","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.535","article-title":"Leonurine affected homocysteine-methionine metabolism based on metabolomics and gut microbiota studies of clinical trial samples","volume":"11","author":"Liao","year":"2021","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.pharmr.2026.100125_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105917","article-title":"Hirsutine ameliorates hepatic and cardiac insulin resistance in high-fat diet-induced diabetic mice and in vitro models","volume":"177","author":"Hu","year":"2022","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100125_bib149","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3350\/cmh.2024.0047","article-title":"Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Zheng","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib150","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cmet.2009.03.012","article-title":"AMPK: an emerging drug target for diabetes and the metabolic syndrome","volume":"9","author":"Zhang","year":"2009","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100125_bib151","first-page":"248","article-title":"AMP-activated protein kinase, fatty acid metabolism, and insulin sensitivity","volume":"20","author":"Smith","year":"2017","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100125_bib152","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1080\/15548627.2025.2466145","article-title":"Buddleoside alleviates nonalcoholic steatohepatitis by targeting the AMPK-TFEB signaling pathway","volume":"21","author":"Chen","year":"2025","journal-title":"Autophagy"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib153","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31749","article-title":"Cordycepin ameliorates nonalcoholic steatohepatitis by activation of the AMP-activated protein kinase signaling pathway","volume":"74","author":"Lan","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100125_bib154","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1002\/hep.32068","article-title":"Gastrodin improves nonalcoholic fatty liver disease through activation of the adenosine monophosphate\u2013activated protein kinase signaling pathway","volume":"74","author":"Wan","year":"2021","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100125_bib155","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1111\/bph.13120","article-title":"Salidroside ameliorates insulin resistance through activation of a mitochondria-associated AMPK\/PI3K\/Akt\/GSK3\u03b2 pathway","volume":"172","author":"Zheng","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100125_bib156","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1002\/hep.32066","article-title":"Salidroside activates the AMP-activated protein kinase pathway to suppress nonalcoholic steatohepatitis in mice","volume":"74","author":"Hu","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2026.100125_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112062","article-title":"Salidroside alleviates taurolithocholic acid 3-sulfate-induced AR42J cell injury","volume":"142","author":"Qian","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100125_bib158","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1016\/j.apsb.2024.05.014","article-title":"Schisanhenol ameliorates non-alcoholic fatty liver disease via inhibiting miR-802 activation of AMPK-mediated modulation of hepatic lipid metabolism","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib159","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/hep.32221","article-title":"Breviscapine alleviates NASH by inhibiting TGF-\u03b2-activated kinase 1-dependent signaling","volume":"76","author":"Lan","year":"2022","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100125_bib160","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s42255-023-00896-7","article-title":"Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice","volume":"5","author":"Yao","year":"2023","journal-title":"Nat Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib161","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.apsb.2023.08.032","article-title":"Identification of a natural PLA2 inhibitor from the marine fungus Aspergillus sp. c1 for MAFLD treatment that suppressed lipotoxicity by inhibiting the IRE-1\u03b1\/XBP-1s axis and JNK signaling","volume":"14","author":"Rao","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.pharmr.2026.100125_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103499","article-title":"Caffeine ameliorates metabolic-associated steatohepatitis by rescuing hepatic Dusp9","volume":"80","author":"Xin","year":"2025","journal-title":"Redox Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib163","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41467-025-55939-2","article-title":"Inhibited peroxidase activity of peroxiredoxin 1 by palmitic acid exacerbates nonalcoholic steatohepatitis in male mice","volume":"16","author":"Yin","year":"2025","journal-title":"Nat Commun"},{"issue":"31","key":"10.1016\/j.pharmr.2026.100125_bib164","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202411984","article-title":"Alnustone ameliorates metabolic dysfunction-associated steatotic liver disease by facilitating mitochondrial fatty acid \u03b2-oxidation via targeting calmodulin","volume":"12","author":"Hu","year":"2025","journal-title":"Adv Sci"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100125_bib165","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"6 Pt B","key":"10.1016\/j.pharmr.2026.100125_bib166","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.semcancer.2013.08.010","article-title":"Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease","volume":"23","author":"Tian","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib167","first-page":"1","article-title":"Nuclear transport proteins: structure, function and disease relevance","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"51","key":"10.1016\/j.pharmr.2026.100125_bib168","doi-asserted-by":"crossref","first-page":"15484","DOI":"10.1021\/acs.jafc.1c06194","article-title":"Propolis: chemical constituents, plant origin, and possible role in the prevention and treatment of obesity and diabetes","volume":"69","author":"Tsuda","year":"2021","journal-title":"J Agric Food Chem"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100125_bib169","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3390\/nu15071644","article-title":"Artepillin C time\u2212dependently alleviates metabolic syndrome in obese mice by regulating CREB\/CRTC2\u2212BMAL1 signaling","volume":"15","author":"Wang","year":"2023","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib170","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41467-021-27533-9","article-title":"A propolis-derived small molecule ameliorates metabolic syndrome in obese mice by targeting the CREB\/CRTC2 transcriptional complex","volume":"13","author":"Chen","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100125_bib171","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70145","article-title":"Carabrone attenuates metabolic dysfunction-associated steatohepatitis by targeting STAT3 in mice","volume":"6","author":"Pan","year":"2025","journal-title":"MedComm"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib172","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","article-title":"Bile acid\u2013microbiota crosstalk in gastrointestinal inflammation and carcinogenesis","volume":"15","author":"Jia","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib173","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1038\/s41467-023-41061-8","article-title":"Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPAR\u03b1 nucleus-cytoplasm shuttling","volume":"14","author":"Zhong","year":"2023","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100125_bib174","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.cmet.2023.07.011","article-title":"Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis","volume":"35","author":"Kuang","year":"2023","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100125_bib175","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00125-016-3912-9","article-title":"Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-\u03b3 and PPAR-\u03b1 agonists on carbohydrate and lipid metabolism in db\/db and diet-induced obese mice","volume":"59","author":"Feng","year":"2016","journal-title":"Diabetologia"},{"issue":"151","key":"10.1016\/j.pharmr.2026.100125_bib176","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jare.2023.02.007","article-title":"Bavachinin protects the liver in NAFLD by promoting regeneration via targeting PCNA","volume":"55","author":"Dong","year":"2024","journal-title":"J Adv Res"},{"key":"10.1016\/j.pharmr.2026.100125_bib177","doi-asserted-by":"crossref","first-page":"0276","DOI":"10.34133\/research.0276","article-title":"Herpetrione, a new type of PPAR\u03b1 ligand as a therapeutic strategy against nonalcoholic steatohepatitis","volume":"6","author":"Linghu","year":"2023","journal-title":"Research"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib178","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202406191","article-title":"Free cholesterol-induced liver injury in non-alcoholic fatty liver disease: mechanisms and a therapeutic intervention using dihydrotanshinone I","volume":"12","author":"Shou","year":"2025","journal-title":"Adv Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib179","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/hep.32651","article-title":"RNA helicase DEAD-box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling","volume":"77","author":"Zhang","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib180","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jhep.2025.01.008","article-title":"Hepatocellular CMPK2 promotes the development of metabolic dysfunction-associated steatohepatitis","volume":"83","author":"Zhu","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115203","article-title":"Ergosterol alleviates hepatic steatosis and insulin resistance via promoting fatty acid \u03b2-oxidation by activating mitochondrial ACSL1","volume":"44","author":"Zheng","year":"2025","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib182","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41467-023-36594-x","article-title":"Itaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic reprogramming","volume":"14","author":"Aso","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100125_bib183","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/ptr.8443","article-title":"Dihydrotanshinone I attenuates diet-induced nonalcoholic fatty liver disease via up-regulation of IRG1","volume":"39","author":"Xiang","year":"2025","journal-title":"Phytother Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib184","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1039\/C5NP00101C","article-title":"Target identification of natural products and bioactive compounds using affinity-based probes","volume":"33","author":"Pan","year":"2016","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.pharmr.2026.100125_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107690","article-title":"Target identification and validation of natural products with label-free methodology: a critical review from 2005 to 2020","volume":"216","author":"Dai","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100125_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2020.107402","article-title":"A comprehensive application: molecular docking and network pharmacology for the prediction of bioactive constituents and elucidation of mechanisms of action in component-based Chinese medicine","volume":"90","author":"Jiao","year":"2021","journal-title":"Comput Biol Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100125_bib187","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1074\/mcp.R120.001936","article-title":"Developments and applications of functional protein microarrays","volume":"19","author":"Syu","year":"2020","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib188","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43586-024-00308-4","article-title":"Photoaffinity labelling with small molecules","volume":"4","author":"Homan","year":"2024","journal-title":"Nat Rev Methods Primers"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100125_bib189","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.tips.2024.09.001","article-title":"Chemical proteomic mapping of reversible small molecule binding sites in native systems","volume":"45","author":"Wozniak","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmr.2026.100125_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2023.100164","article-title":"Activity-based protein profiling: a graphical review","volume":"5","author":"Porta","year":"2023","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib191","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41592-024-02553-7","article-title":"A peptide-centric local stability assay enables proteome-scale identification of the protein targets and binding regions of diverse ligands","volume":"22","author":"Li","year":"2025","journal-title":"Nat Methods"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100125_bib192","article-title":"Camu-camu decreases hepatic steatosis and liver injury markers in overweight, hypertriglyceridemic individuals: a randomized crossover trial","volume":"5","author":"Agrinier","year":"2024","journal-title":"Cell Rep Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100125_bib193","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/d41573-025-00088-w","article-title":"Amylin takes another shot at the obesity prize","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"10317","key":"10.1016\/j.pharmr.2026.100125_bib194","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"issue":"10520","key":"10.1016\/j.pharmr.2026.100125_bib195","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/S0140-6736(25)02155-5","article-title":"Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Billings","year":"2025","journal-title":"Lancet"},{"issue":"10499","key":"10.1016\/j.pharmr.2026.100125_bib196","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study","volume":"406","author":"Dahl","year":"2025","journal-title":"Lancet"},{"issue":"10499","key":"10.1016\/j.pharmr.2026.100125_bib197","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(25)01250-4","article-title":"GLP-1 and amylin receptor multiagonism with amycretin for obesity management","volume":"406","author":"Khoo","year":"2025","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100125_bib198","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib199","article-title":"Vitamin E (300 mg) in the treatment of MASH: a multi-center, randomized, double-blind, placebo-controlled study","volume":"6","author":"Song","year":"2025","journal-title":"Cell Rep Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100125_bib200","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s42255-024-00988-y","article-title":"Resistant starch intake facilitates weight loss in humans by reshaping the gut microbiota","volume":"6","author":"Li","year":"2024","journal-title":"Nat Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100082","article-title":"Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases","volume":"77","author":"Steven","year":"2025","journal-title":"Pharmacol Rev"},{"issue":"10403","key":"10.1016\/j.pharmr.2026.100125_bib202","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100125_bib203","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100125_bib204","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100125_bib205","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMc2509454","article-title":"Semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"393","author":"Luo","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100125_bib206","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Jara","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib207","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2337\/dci24-0091","article-title":"Compounded GLP-1 and dual GIP\/GLP-1 receptor agonists: a statement from the American Diabetes Association","volume":"48","author":"Neumiller","year":"2025","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100125_bib208","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100125_bib209","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100125_bib210","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial","volume":"332","author":"Zhao","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib211","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib212","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100125_bib213","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100125_bib214","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100125_bib215","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib216","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"issue":"10520","key":"10.1016\/j.pharmr.2026.100125_bib217","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/S0140-6736(25)02114-2","article-title":"Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (Impact): 24-week results from a multicentre, randomised, double-blind, phase 2b study","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib218","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54080-w","article-title":"The dual GLP-1\/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk","volume":"15","author":"Valdecantos","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmr.2026.100125_bib219","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101691","article-title":"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A dose phase 1b trial","volume":"54","author":"Ji","year":"2022","journal-title":"EClinicalmedicine"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib220","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat Commun"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100125_bib221","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-weekly mazdutide in Chinese ADULTS WITH OBESITY OR OVERWEIGHT","volume":"392","author":"Ji","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100125_bib222","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013hormone-receptor agonist retatrutide for obesity \u2014 A phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100125_bib223","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100125_bib224","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2021.12.004","article-title":"A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH","volume":"76","author":"Fraser","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib225","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2025.01.032","article-title":"A phase IIb randomised-controlled trial of the FFAR1\/FFAR4 agonist icosabutate in MASH","volume":"83","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib226","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","article-title":"Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH)","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib227","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and \u2212\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100125_bib229","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100125_bib230","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2024.12.045","article-title":"Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD","volume":"82","author":"Barb","year":"2025","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100125_bib231","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jhep.2025.03.003","article-title":"Metabolic effects and mechanism of action of the pan-PPAR agonist lanifibranor","volume":"82","author":"Sabatini","year":"2025","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100125_bib232","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17425247.2016.1178233","article-title":"Bile acids and bile acid derivatives: use in drug delivery systems and as therapeutic agents","volume":"13","author":"Faustino","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"issue":"10215","key":"10.1016\/j.pharmr.2026.100125_bib233","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100125_bib234","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.cgh.2021.07.020","article-title":"Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"811","key":"10.1016\/j.pharmr.2026.100125_bib235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adn4558","article-title":"FXR adapts hepatic mitochondrial function to increased substrate oxidation in patients with obesity","volume":"17","author":"Panzitt","year":"2025","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib236","doi-asserted-by":"crossref","first-page":"390","DOI":"10.14309\/ajg.0000000000003029","article-title":"Cobalt: a confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls","volume":"120","author":"Kowdley","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pharmr.2026.100125_bib237","first-page":"1","article-title":"Bile acid signaling in MASLD: from pathogenesis to therapeutic applications","author":"Simbrunner","year":"2025","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib238","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100125_bib239","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100125_bib240","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1055\/s-0041-1731707","article-title":"Role of FXR in bile acid and metabolic homeostasis in NASH: pathogenetic concepts and therapeutic opportunities","volume":"41","author":"Radun","year":"2021","journal-title":"Semin Liver Dis"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib241","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100125_bib242","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jhep.2025.06.010","article-title":"The history and future of bile acid therapies","volume":"83","author":"Beuers","year":"2025","journal-title":"J Hepatol"},{"issue":"10481","key":"10.1016\/j.pharmr.2026.100125_bib243","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(25)00397-6","article-title":"Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100125_bib244","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","article-title":"Preclinical models of non-alcoholic fatty liver disease","volume":"68","author":"Santhekadur","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100125_bib245","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/gutjnl-2023-331090","article-title":"Metabolic dysfunction-associated steatotic liver disease in children","volume":"74","author":"Goyal","year":"2025","journal-title":"Gut"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003169972600013X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003169972600013X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:39:35Z","timestamp":1779446375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003169972600013X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":244,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S003169972600013X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100125","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging natural products against obesity and metabolic dysfunction-associated steatotic liver disease\/metabolic dysfunction-associated steatohepatitis: Direct target discovery and mechanistic insights","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100125"}}